Certo, Michelangelo http://orcid.org/0000-0002-5568-3465
Tsai, Chin-Hsien
Pucino, Valentina http://orcid.org/0000-0002-7683-4568
Ho, Ping-Chih http://orcid.org/0000-0003-3078-3774
Mauro, Claudio http://orcid.org/0000-0002-3736-0099
Article History
Accepted: 16 July 2020
First Online: 24 August 2020
Competing interests
: P.-C.H. is scientific adviser for Elixiron Immunotherapeutics and receives research funding from Roche. P.-C.H. has received honorarium from Chungai and Pfizer. The other authors declare no competing interests.